Hikma Pharmaceuticals PLC announced the granting of discretionary share awards under its 2023 Long Term Incentive Plan (LTIP) and Deferred Bonus Plan (DBP) to key managerial personnel. These awards, ...

Ahead of a planned trial next month, Jazz Pharmaceuticals is moving to resolve antitrust allegations surrounding its key ...

AMMAN — Hikma Pharmaceuticals PLC (Hikma) on Wednesday announced an exclusive licensing agreement with pharmaand GmbH (pharma ...

Hikma Pharmaceuticals PLC HIK shares dropped 3.64% to £17.74 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100 Index UKX falling 2.92% to ...

Jazz is being accused of anti-competitive practices regarding its narcolepsy drug, as generic competitors emerge on the ...

Hikma Pharmaceuticals PLC HIK shares slipped 1.68% to £19.86 Monday, on what proved to be an all-around rough trading session for the stock market, with the FTSE 100 Index UKX falling 0.10% to ...

Jazz Pharma has agreed to pay $145 million to settle lawsuits claiming it illegally acted to prevent generic versions of its ...

Jefferies raises Hikma Pharmaceutical to 'buy' (hold) - price target 2,400 (2,090) pence Jefferies cuts Peterhill Partners price target to 250 (280) pence - 'buy' ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be intrigued to know that Hikma Pharmaceuticals PLC (LON:HIK) is about to go ex ...

Amman – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has announced an exclusive licensing ...